OptimizeRx Recognized by Digital Health Awards® Fall 2021 for TelaRep™ and its COVID-19 Text Message Campaign
- COVID-19 Consumer Health Communications Campaign won silver in the “Mobile Digital Health Resources: Text Messaging” category
- TelaRep Interactive EHR Communication received a merit award in the “Connected Digital Health: Clinical Decision Support Tools” category
OptimizeRx earned the silver award for its COVID-19 automated text messaging campaign. The campaign, implemented in response to the pandemic, delivered mobile digital health resources to communities across the
TelaRep’s merit award in the “Connected Digital Health: Clinical Decision Support Tools” highlights the value of the award-winning digital tool which has also been recognized as one of the most innovative products for life sciences. TelaRep is a HIPAA-compliant, secure, virtual connection that gives prescribers a “one-click” ability to reach out to the right pharma contact any time they have a need, without leaving their electronic workflow. This line of communication allows physicians to receive important support when determining the best treatment regimen for a patient. TelaRep is the only digital healthcare communications solution that allows interactive communications between HCPs and manufacturers to be initiated from within the EHR clinical workflow.
The Digital Health Awards competition is held twice each year, participants include hundreds of local, state and national health-related organizations and companies. Recent winners have included
- AI-directed, real-time HCP marketing to raise awareness of treatment benefits to give patients a timely start on therapy
- Streamlined communication and processes around therapy initiation to reduce abandonment through simplified enrollment
- Personalized, successful adherence programs to help patients stay on their doctor-recommended course of therapy
For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Andy D’Silva, SVP Corporate Finance
Media Relations Contact
Investor Relations Contact
Source: OptimizeRx Corporation